CagrilintidevsRetatrutide

Cagrilintide is a long-acting analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells after meals. Native amylin plays a crucial but often overlooked role in metabolic regulation — it signals satiety, slows gastric emptying, and suppresses post-meal glucagon secretion through mechanisms entirely distinct from the GLP-1 pathway.

Cagrilintide activates amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptors are concentrated in the area postrema and the nucleus tractus solitarius in the brainstem — regions outside the blood-brain barrier that can directly sense circulating peptides. Activation of these neurons triggers ascending satiety signals to the hypothalamus, reducing meal size and food-seeking behavior through pathways that are neuroanatomically separate from GLP-1 signaling.

This distinct mechanism is why cagrilintide produces additive appetite suppression when combined with semaglutide (as CagriSema) — the two peptides target different populations of neurons within the brain's appetite control circuitry. Cagrilintide has been engineered with acylation modifications that enable albumin binding, extending its half-life from minutes (native amylin) to approximately one week, making it suitable for weekly subcutaneous dosing.

Retatrutide is a triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors — the first molecule to target all three pathways. Each receptor system contributes distinct metabolic effects that combine to produce unprecedented weight loss results in clinical trials.

The GLP-1 component suppresses appetite through hypothalamic signaling and slows gastric emptying, while the GIP component enhances beta-cell insulin secretion and may improve lipid handling in adipose tissue. What sets retatrutide apart is the addition of glucagon receptor agonism. Glucagon receptors in the liver stimulate glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation. In brown and beige adipose tissue, glucagon signaling drives thermogenesis — literally increasing the body's energy expenditure by converting calories to heat rather than storing them as fat.

The glucagon component also has significant implications for liver health, as it directly promotes the breakdown of hepatic triglycerides, making retatrutide particularly promising for metabolic-associated steatotic liver disease (MASLD/NASH). The molecular design balances the three receptor affinities carefully — too much glucagon agonism could raise blood glucose, but the concurrent GLP-1 and GIP activation provides sufficient insulinotropic counterbalance to maintain glycemic control. Phase 2 trials demonstrated up to 24% body weight reduction at the highest dose, representing the largest weight loss achieved by any anti-obesity medication to date.